Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Ohio: - Summa Health System - Akron Campus — Akron, Ohio
- Cleveland Clinic Akron General — Akron, Ohio
- Aultman Alliance Community Hospital — Alliance, Ohio
- OhioHealth O'Bleness Hospital — Athens, Ohio
- Summa Health System - Barberton Campus — Barberton, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Ohio: - OhioHealth O'Bleness Hospital — Athens, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Geauga Hospital — Chardon, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Bethesda North Hospital — Cincinnati, Ohio
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- OhioHealth O'Bleness Hospital — Athens, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Adena Regional Medical Center — Chillicothe, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
- Dayton Children's Hospital — Dayton, Ohio
Phase 3 Recruiting Industry
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…
Sponsor: AbbVie
NCT ID: NCT05445778
Sites in Ohio: - University of Cincinnati /ID# 269578 — Cincinnati, Ohio
- Jamescare Gynecologic Oncology At Mill Run /ID# 269105 — Hilliard, Ohio
- Kettering Medical Center /ID# 269585 — Kettering, Ohio
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Ohio: - UH Geauga Medical Center — Chardon, Ohio
- University of Cincinnati Medical Center — Cincinnati, Ohio
- TriHealth Cancer Institute - Good Samaritan Hospital — Cincinnati, Ohio
- TriHealth Cancer Institute- Thomas Comprehensive Care Center — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 2, Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Ohio: - Ohio State University Wexner Medical Center — Hilliard, Ohio
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Ohio: - Cleveland Clinic Foundation — Cleveland, Ohio
- Ohio State — Hilliard, Ohio
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- OhioHealth Research Institute — Columbus, Ohio
- Kettering Health — Kettering, Ohio
- ProMedica Flower Hospital — Sylvania, Ohio
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Ohio: - University of Cincinnati Medical Center ( Site 0090) — Cincinnati, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054) — Columbus, Ohio
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…
Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in Ohio: - Research Site — Dayton, Ohio
- Research Site — Sylvania, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Industry
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 pr…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT07546500
Sites in Ohio: - Site 0108 — Columbus, Ohio
Phase 3 Recruiting Industry
This Phase 3 study will be conducted in different countries around the world with up to about 528 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of…
Sponsor: Genmab
NCT ID: NCT07225270
Sites in Ohio: - Miami Valley Hospital South — Centerville, Ohio
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Ohio: - OhioHealth O'Bleness Hospital — Athens, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Aultman Health Foundation — Canton, Ohio
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Ohio: - UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Ohio: - Site 0147 - Trihealth Cancer Institute - Harold and Eugen — Cincinnati, Ohio
- Site 0243 - Mark H Zangmeister Cancer Center — Columbus, Ohio
- Site 0214-Ohio State University Comprehensive Cancer Center — Hilliard, Ohio
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Ohio: - Oncology Hematology Care, Inc — Cincinnati, Ohio
- The Mark H Zangmeister Cancer Center Ohio — Columbus, Ohio
- The Ohio State University Wexner Medical Center Division of Gynecologic Oncology — Hilliard, Ohio
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Ohio: - Oncology Hematology Care Primary — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Ohio: - Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Ohio: - The Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Ohio: - Research Site 138 — Canton, Ohio
- Research Site 113 — Cincinnati, Ohio
- Research Site 131 — Dayton, Ohio
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Ohio: - UH Cleveland Medical Center — Cleveland, Ohio
- Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
Phase 2 Recruiting Industry
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Sponsor: TORL Biotherapeutics, LLC
NCT ID: NCT06690775
Sites in Ohio: - The James Cancer Hospital and Solove Research Institute - Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio